This therapeutic approach is based on the rationale that JAK-STAT mediated signaling regulates multiple cytokine-dependent pathways involved in the pathogenesis of IBD, including IL-6, IL-10, and IL-23 [44], and such inhibitors are able to target multiple immune pathways simultaneously to improve response in patients. Here, IL6 is linked to inflammatory bowel disease.